Arcturus Therapeutics (ARCT) Financials

Arcturus Therapeutics (NASDAQ:ARCT) remains in a development-stage financial profile, with recurring operating losses and negative operating cash flow. The latest quarter showed some sequential improvement in losses and research spending, but revenue declined sharply from the same period a year earlier and cash reserves continued to fall.

Revenue and profitability: Q2 2026 revenue was $3.0 million, up from $2.1 million in Q1 2026 but down approximately 90% from $28.3 million in Q2 2025. Revenue has been highly volatile, ranging from $2.1 million to $49.9 million across the reported quarterly periods. The company posted a $25.5 million operating loss and a $23.8 million net loss in Q2 2026. Although the net loss improved from $27.0 million in Q1, it was substantially worse than the $9.2 million loss reported in restated Q2 2025.

Operating expenses declined sequentially to $28.5 million in Q2 2026 from $31.0 million in Q1. Research and development expense fell to $17.5 million from $21.5 million, while selling, general and administrative expense increased to $11.0 million from $9.5 million. The lower R&D spending helped reduce the quarterly loss, but the company has not yet demonstrated sustained operating leverage or profitability.

Cash flow and liquidity: Arcturus used $19.9 million in operating cash during Q2 2026, broadly consistent with the $19.4 million used in Q1. This was an improvement from the $30.1 million operating cash outflow in Q2 2024, but worse than the $5.8 million outflow in restated Q2 2025. With $191.5 million of cash and equivalents at June 30, 2026, the company had substantial liquidity, though a simple comparison with the latest quarterly operating burn suggests roughly 9 to 10 quarters of cash coverage before considering changes in spending, revenue, financing, or working capital.

Balance sheet: Cash declined from $288.4 million in Q1 2024 to $191.5 million in Q2 2026, while total assets fell from $418.8 million to $224.3 million over the same period. The latest balance sheet showed $52.5 million of total liabilities and $171.8 million of equity. No debt was reported in Q2 2026, compared with $15.0 million of long-term debt in Q1 2025 that was subsequently repaid. However, accumulated retained earnings declined to negative $565.3 million, reflecting the company’s long history of losses.

• Sequential loss improvement: Q2 2026 net loss narrowed to $23.8 million from $27.0 million in Q1, while the operating loss improved to $25.5 million from $28.9 million.
• Lower research spending: R&D expense declined to $17.5 million in Q2 2026 from $21.5 million in Q1 and $29.6 million in restated Q2 2025, helping reduce the quarterly cash burden.
• Debt-free balance sheet: Arcturus reported no short-term or long-term debt in Q2 2026, limiting interest and refinancing risk.
• Meaningful liquidity position: The company held $191.5 million in cash and equivalents, providing funding capacity for ongoing research and development.
• Interest income remains helpful: Interest and investment income contributed $1.8 million in Q2 2026, partially offsetting the operating loss, although this benefit may decline as cash balances fall or interest rates change.
• Revenue is uneven: Quarterly revenue has fluctuated significantly, suggesting that licensing, collaboration, or milestone-related revenue may not be recurring or predictable.
• Sharp year-over-year revenue decline: Q2 2026 revenue fell approximately 90% from Q2 2025, reducing the company’s ability to offset research and corporate expenses.
• Persistent operating cash burn: Operating cash outflows remained near $20 million per quarter in the first half of 2026, meaning the company continues to consume cash without internally funding operations.
• Long-term losses continue to accumulate: Retained earnings deteriorated to negative $565.3 million in Q2 2026 from negative $394.7 million in Q1 2024.
• Potential dilution risk: Weighted average shares outstanding increased to approximately 28.4 million in Q2 2026 from 26.9 million in Q1 2024, and additional equity financing could be needed if cash burn remains elevated.

Overall, ARCT’s financial position is supported by a debt-free balance sheet and nearly $200 million of cash, but the company remains dependent on its pipeline, partnerships, and potential future financing. Investors should closely monitor revenue consistency, quarterly cash burn, progress toward commercial revenue, and changes in shares outstanding.